← Leaderboards
Sharad Khare
Harry S. Truman Memorial Va Hospital
$566,663
Attributed
$566,663
Total exposure
5
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $146.1K · FY2010–25$200K$150K$100K$50K$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$566,663 · 4
VA$0 · 1
By mechanism
R03$566,663 · 4
I01$0 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsTumorAzoxymethaneInvestigationCancer EtiologyRegulationGrowthUnited StatesProteinsCancer CellTumor ProgressionIn VivoTherapeutic InterventionTumorigenesisCancer PatientRecurrenceCarcinogenesisColorectal CancerGenesColon CarcinomaMouse ModelReceptor Protein-Tyrosine KinasesAttentionPrevent
Grant awards (18)
Sprouty: Putative Oncogene in Colorectal Cancer$0
I01 · FY2025 · VA · contact PI
Sprouty: Putative Oncogene in Colorectal Cancer$0
I01 · FY2024 · VA · contact PI
Deciphering the role of Sprouty2 in CRC progression, treatment and recurrence$146,110
R03 · FY2020 · CA · contact PI
SPROUTY: PUTATIVE ONCOGENE IN COLORECTAL CANCER$0
I01 · FY2020 · VA · contact PI
SPROUTY: PUTATIVE ONCOGENE IN COLORECTAL CANCER$0
I01 · FY2019 · VA · contact PI
Colorectal Cancer: Characterization of a new Cre-LoxP Model$61,021
R03 · FY2018 · CA · contact PI
SPROUTY: PUTATIVE ONCOGENE IN COLORECTAL CANCER$0
I01 · FY2018 · VA · contact PI
Colorectal Cancer: Characterization of a new Cre-LoxP Model$60,790
R03 · FY2017 · CA · contact PI
SPROUTY: PUTATIVE ONCOGENE IN COLORECTAL CANCER$0
I01 · FY2017 · VA · contact PI
Colon Cancer Chemoprevention and COX-2 Suppression by Ursodeoxycholic Acid$0
I01 · FY2015 · VA · contact PI
Colon Cancer Chemoprevention and COX-2 Suppression by Ursodeoxycholic Acid$0
I01 · FY2014 · VA · contact PI
Colon Cancer Chemoprevention and COX-2 Suppression by Ursodeoxycholic Acid$0
I01 · FY2013 · VA · contact PI
Colon Cancer Chemoprevention and COX-2 Suppression by Ursodeoxycholic Acid$0
I01 · FY2012 · VA · contact PI
Colon Cancer Chemoprevention$71,492
R03 · FY2011 · CA · contact PI
Colon Cancer Chemoprevention$74,750
R03 · FY2010 · CA · contact PI
Colon Cancer Chemoprevention by Ursodeoxycholic Acid$58,937
R03 · FY2003 · CA
Colon Cancer Chemoprevention by Ursodeoxycholic Acid$17,313
R03 · FY2003 · CA
Colon Cancer Chemoprevention by Ursodeoxycholic Acid$76,250
R03 · FY2002 · CA